Cytokines
Biomarkers play a key role in improving medical product development
“Biomarkers are emerging as an essential tool to boost efficiency in the field of drug discovery. Around 90 per cent of new compounds fail during the clinical trials, predominantly related to absorption, distribution, metabolism, excretion (ADME) and toxicology issues. Increasing the performance of biomarker immunoassays will increase the significance of the results and furthermore could enable the establishment of new biomarkers.” [Frost & Sullivan, Strategic Analysis of Biomarkers in Clinical Trials]
Typical biomarkers are inflammatory proteins like cytokines. As these markers are often only hardly detectable with commercial ELISA kits Imperacer® could improve the significance of your results by improving the immunoassay performance.
A typical performance of Imperacer® development kits on e.g. the detection of Interleukins is shown in the standard curves. The assay can be adopted/developed for any biomarker of your choice!
Standard curves for the detection of human Tumornecrosisfactor alpha (TNFα) and Interleukin 6 (IL-6) in human serum using the Imperacer® System.
